Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

F. Ravandi, A. Pigneux, D. J. De Angelo, E. Raffoux, J. Delaunay, X. Thomas, T. Kadia, H. Kantarjian, J. Scheuenpflug, C. Zhao, W. Guo, B. D. Smith

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Article numbere375
JournalBlood cancer journal
Volume5
Issue number12
DOIs
StatePublished - Dec 11 2015

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this